These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 26000151)

  • 1. Skin CD30(+) T cells and circulating levels of soluble CD30 are increased in patients with graft versus host disease.
    Amedei A; Pimpinelli N; Grassi A; Bella CD; Niccolai E; Brancati S; Benagiano M; D'Elios S; Bosi A; D'Elios MM
    Auto Immun Highlights; 2014 Jun; 5(1):21-6. PubMed ID: 26000151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating levels of soluble CD30 are increased in patients with localized scleroderma and correlated with serological and clinical features of the disease.
    Ihn H; Yazawa N; Kubo M; Yamane K; Sato S; Fujimoto M; Kikuchi K; Soma Y; Tamaki K
    J Rheumatol; 2000 Mar; 27(3):698-702. PubMed ID: 10743811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cutaneous CD30+ cells in children with atopic dermatitis.
    Cavagni G; Caffarelli C; Facchetti F; Brugnoni D; Notarangelo LD; Tosoni C; Altobelli R
    Int Arch Allergy Immunol; 2000 Mar; 121(3):224-8. PubMed ID: 10729781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Value of soluble CD30 in liver transplantation.
    Fábrega E; Unzueta MG; Cobo M; Casafont F; Amado JA; Romero FP
    Transplant Proc; 2007 Sep; 39(7):2295-6. PubMed ID: 17889168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble CD30 serum levels in atopic dermatitis and bronchial asthma and its relationship with disease severity in pediatric age.
    Heshmat NM; El-Hadidi ES
    Pediatr Allergy Immunol; 2006 Jun; 17(4):297-303. PubMed ID: 16771784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Release of soluble CD30 after allogeneic stimulation is mediated by memory T cells and regulated by IFN-γ and IL-2.
    Velásquez SY; García LF; Opelz G; Alvarez CM; Süsal C
    Transplantation; 2013 Jul; 96(2):154-61. PubMed ID: 23857000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating soluble-CD30 (sCD30) in patients with HCV-related chronic hepatitis and in patients with alcoholic liver disease.
    De Lazzari F; Ravagnan P; Tenderini M; Vicarioto MA; Galliani EA; Lorenzoni U; Popovic A; Floreani A
    Hepatogastroenterology; 2002; 49(43):231-4. PubMed ID: 11941962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble CD30 and cyclosporine in severe atopic dermatitis.
    Caproni M; Salvatore E; Cardinali C; Brazzini B; Fabbri P
    Int Arch Allergy Immunol; 2000 Apr; 121(4):324-8. PubMed ID: 10828723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunological monitoring after organ transplantation: potential role of soluble CD30 blood level measurement.
    Truong DQ; Darwish AA; Gras J; Wieërs G; Cornet A; Robert A; Mourad M; Malaise J; de Ville de Goyet J; Reding R; Latinne D
    Transpl Immunol; 2007 Jun; 17(4):283-7. PubMed ID: 17493532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of high post-transplant soluble CD30 serum levels with chronic allograft nephropathy.
    Grenzi PC; Campos ÉF; Tedesco-Silva H; Felipe CR; Franco MF; Soares MF; Medina-Pestana JO; Gerbase-Delima M
    Transpl Immunol; 2013 Dec; 29(1-4):34-8. PubMed ID: 23928467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective study of serum soluble CD30 in allogeneic hematopoietic stem cell transplantation.
    Hübel K; Cremer B; Heuser E; von Strandmann EP; Hallek M; Hansen HP
    Transpl Immunol; 2010 Aug; 23(4):215-9. PubMed ID: 20620210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TH1/TH2 cytokines and soluble CD30 levels in kidney allograft patients with donor bone marrow cell infusion.
    Solgi G; Amirzagar AA; Pourmand G; Mehrsai AR; Taherimahmoudi M; Baradaran N; Nicknam MH; Ebrahimi Rad MR; Saraji A; Asadpoor AA; Moheiydin M; Nikbin B
    Transplant Proc; 2009 Sep; 41(7):2800-4. PubMed ID: 19765439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble CD30 as a predictor of kidney graft outcome.
    Pelzl S; Opelz G; Wiesel M; Schnülle P; Schönemann C; Döhler B; Süsal C
    Transplantation; 2002 Jan; 73(1):3-6. PubMed ID: 11792970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-tumor necrosis factor-alpha response in rheumatoid arthritis is associated with an increase in serum soluble CD30.
    Gerli R; Lunardi C; Bocci EB; Bobbio-Pallavicini F; Schillaci G; Caporali R; Bistoni O; Pirro M; Pitzalis C; Montecucco C
    J Rheumatol; 2008 Jan; 35(1):14-9. PubMed ID: 18061981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pre-transplant soluble CD30 is associated with bronchiolitis obliterans syndrome after lung transplantation.
    Bauwens AM; van de Graaf EA; van Ginkel WG; van Kessel DA; Otten HG
    J Heart Lung Transplant; 2006 Apr; 25(4):416-9. PubMed ID: 16563971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Age-dependent changes of serum soluble CD30 concentration in children.
    Chrul S; Polakowska E
    Pediatr Transplant; 2011 Aug; 15(5):515-8. PubMed ID: 21672104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble CD30 and HLA antibodies as potential risk factors for kidney transplant rejection.
    Slavcev A; Lácha J; Honsová E; Sajdlová H; Lodererová A; Vitko S; Skibová J; Striz I
    Transpl Immunol; 2005 Jun; 14(2):117-21. PubMed ID: 15935302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pretransplant soluble CD30 level has limited effect on acute rejection, but affects graft function in living donor kidney transplantation.
    Kim MS; Kim HJ; Kim SI; Ahn HJ; Ju MK; Kim HJ; Jeon KO; Kim YS
    Transplantation; 2006 Dec; 82(12):1602-5. PubMed ID: 17198243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High serum soluble CD30 does not predict acute rejection in liver transplant patients.
    Matinlauri I; Höckerstedt K; Isoniemi H
    Transplant Proc; 2006 Dec; 38(10):3601-4. PubMed ID: 17175343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating levels of soluble CD30, a marker of cells producing Th2-type cytokines, are increased in patients with systemic lupus erythematosus and correlate with disease activity.
    Caligaris-Cappio F; Bertero MT; Converso M; Stacchini A; Vinante F; Romagnani S; Pizzolo G
    Clin Exp Rheumatol; 1995; 13(3):339-43. PubMed ID: 7554561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.